Guidelines for the Screening Care and Treatment of Persons with Hepatitis C Infection : Apr-14.

Cover -- CONTENTS -- ACKNOWLEDGEMENTS -- ABBREVIATIONS AND ACRONYMS -- GLOSSARY OF TERMS -- EXECUTIVE SUMMARY -- 1. SCOPE AND OBJECTIVES -- 2. BACKGROUND -- 2.1 Epidemiology of hepatitis C -- 2.1.1 Routes of transmission -- 2.1.2 Coinfections -- 2.2 Hepatitis C virus -- 2.3 Natural history of HCV infection -- 2.4 Prevention of HCV infection -- 2.5 Screening for HCV infection -- 2.6 Care of patients with HCV infection -- 2.7 Treatment of patients with HCV infection -- 2.8 Cost-effectiveness of treatment -- 3. GUIDING PRINCIPLES -- 3.1 Human rights -- 3.2 Access to health care -- 3.3 Service provision -- 3.4 Integrated health care -- 4. METHODS -- 5. RECOMMENDATIONS ON SCREENING -- 5.1 Screening to identify persons with HCV infection -- 5.2 When to confirm a diagnosis of chronic HCV infection -- 6. RECOMMENDATIONS ON CARE OF PEOPLE INFECTED WITH HCV -- 6.1 Screening for alcohol use and counselling to reduce moderate and high levels of alcohol intake -- 6.2 Assessing the degree of liver fibrosis and cirrhosis -- 7. RECOMMENDATIONS ON TREATMENT -- 7.1 Assessment for HCV treatment -- 7.2 Treatment with pegylated interferon and ribavirin -- 7.3 Treatment with telaprevir or boceprevir -- 7.4 Introduction to recommendations concerning sofosbuvir and simeprevir -- 7.5 Treatment with sofosbuvir -- 7.6 Treatment with simeprevir -- 8. CLINICAL CONSIDERATIONS -- 8.1 Monitoring for toxicity -- 8.2 Dose modification -- 8.3 Monitoring for efficacy -- 9. SPECIAL CONSIDERATIONS FOR SPECIFIC POPULATIONS -- 9.1 People who inject drugs -- 9.2 Persons with HIV and HCV coinfection -- 9.3 Children and adolescents -- 9.4 Persons with liver cirrhosis -- 9.5 Persons with HBV and TB coinfection -- 9.6 Persons with renal impairment -- 10. OPERATIONAL AND IMPLEMENTATION ISSUES -- 10.1 Service planning -- 10.2 Service delivery -- 10.3 Future considerations.

10.4 Dissemination, monitoring and implementation of the Guidelines -- 11. REFERENCES.

These are the first WHO guidelines on the screening care and treatment of persons with HCV infection. They are intended to complement existing guidance on the primary prevention of HCV and other bloodborne viruses by improving blood and injection safety and health care for people who inject drugs (PWID) and other vulnerable groups including those living with HIV (see section 2.4 for related WHO guidelines). These guidelines are primarily targeted at policy-makers in ministries of health working in low- and middle-income countries who formulate country-specific treatment guidelines and who plan infectious diseases treatment programmes. These guidelines are intended to assist officials as they develop national hepatitis C treatment plans and policy and guideline documents. In addition it is anticipated that nongovernmental agencies and health professionals organizing treatment and screening services for hepatitis C will use the guidelines to define the necessary elements of such services. These guidelines will also be a useful resource for clinicians who manage persons with HCV infection. This guidelines document will be revised in 2016. Because a number of new medicines are expected to become available in the meantime WHO will issue interim guidance twelve months after publication of these guidelines to provide recommendations regarding newly approved medicines.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.